The Incretin Franchise (GLP-1)Wide moat

Lilly's position in the incretin class — the diabetes and weight-loss medicines that have captured the world's attention — is the rarest kind of advantage a drug company can hold: a patent-protected lead in a category of vast and still-growing demand. It is one thing to own a monopoly on a medicine that treats a modest condition; it is another entirely to own a commanding position in what may be one of the largest pharmaceutical markets ever to develop. The scale of the opportunity is what makes this franchise so extraordinary.

The defining feature of the moment is that demand is so vast the constraint is supply. For most products, a company's challenge is finding enough customers; here, the challenge is manufacturing enough medicine to serve the customers already clamoring for it. When the market limitation is how fast you can build capacity rather than how many buyers you can attract, you are in an enviable position indeed — and it is one that rewards the company that invested early and aggressively in the ability to produce at scale.

Being first and best in a category this large confers advantages that compound and that late entrants must struggle to overcome. Scale in manufacturing, a growing body of clinical data, and — crucially — familiarity among the physicians who prescribe all accrue to the early leader. Doctors reach first for the treatment they know, have prescribed before, and trust, and that habit of prescription is a real and durable advantage that a newcomer, however capable its own drug, must work hard and long to displace.

That physician familiarity is worth dwelling on, because it functions much like a brand in a market where the customer, in effect, is the prescribing doctor. A physician who has seen a medicine work in her own patients, who understands its dosing and its effects, and who trusts its maker will reach for it by default — and shifting that default is slow, evidence-hungry work. The incumbent's relationship with the medical profession is a moat that sits atop the patent moat, and it outlasts the mere novelty of being first.

Competitors are coming, as they always do in a market this attractive, and an honest appraisal expects them. But a multi-year head start in a market of this size is worth a very great deal, and Lilly is not standing still: it is already developing the next-generation medicines meant to extend the lead beyond the current drugs. The franchise is not a single product to be defended but a position to be built upon, and the company that leads today has both the resources and the head start to keep leading — provided it keeps running, which in this industry is always the condition attached to every advantage — Mounjaro alone rose 91% to $9.94 billion in the second quarter of 2026.¹